Legal Opinion
Ucb, Inc. v. Watson Laboratories Inc.
Court of Appeals for the Federal Circuit
Decided June 24, 2019No. 2018-1397, 2018-1453PublishedCited by 21 opinions
1Opinion of the Court
Chen, Circuit Judge.
*1275 This appeal concerns UCB, Inc., UCB Manufacturing Ireland Limited, UCB Pharma GmbH, and LTS Lohman Therapie-Systeme AG (UCB)'s U.S. Patent Nos. 6,884,434 1 and 8,232,414. 2 The '434 patent claims a transdermal therapeutic system comprising rotigotine, a drug used for the treatment of Parkinson's disease. The '414 patent claims a polymorph of rotigotine. The United States District Court for the District of Delaware found that Watson Laboratories Inc. and Actavis Laboratories UT, Inc. (Actavis)'s generic products infringed the '434 patent under the doctrine of equivalents.…
2Cases cited30 opinions
- Graver Tank & Mfg. Co. v. Linde Air Products Co.Supreme Court of the United States · 1950
- Warner-Jenkinson Co. v. Hilton Davis Chemical Co.Supreme Court of the United States · 1997
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Coffin v. OgdenSupreme Court of the United States · 1874
- Pfizer, Inc. v. Apotex, Inc.Court of Appeals for the Federal Circuit · 2007
25 more not listed; retrieve them via the Exa API.
3Cited by21 opinions
- Eli Lilly and Company v. Hospira, Inc.Court of Appeals for the Federal Circuit · 2019
- Basf Corporation v. Snf Holding CompanyCourt of Appeals for the Federal Circuit · 2020
- Edgewell Personal Care Brands v. Munchkin, Inc.Court of Appeals for the Federal Circuit · 2021
- Aoki v. GilbertDistrict Court, E.D. California · 2020
- Bio-Rad Laboratories, Inc. v. 10x Genomics Inc.Court of Appeals for the Federal Circuit · 2020
16 more not listed; retrieve them via the Exa API.